Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13988548 | 0.80 | KMT2A (0.44) | KMT2AALDH1A1MAPK1MAOBMAPT | |
| SCHEMBL4913458 | 0.74 | KMT2A (0.56) | KMT2AALDH1A1MAPK1MAOBMAPT | |
| SCHEMBL13988540 | 0.72 | KMT2A (0.46) | KMT2AALDH1A1MAPK1MAOBMAPT | |
| SCHEMBL14015244 | 0.71 | KMT2A (0.46) | KMT2AALDH1A1MAPK1MAOBMAPT | |
| SCHEMBL13988542 | 0.71 | KMT2A (0.43) | KMT2AALDH1A1MAPK1MAOBMAPT | |
| SCHEMBL13988536 | 0.70 | KMT2A (0.52) | KMT2AALDH1A1MAPK1MAOBMAPT | |
| SCHEMBL4577413 | 0.70 | KDM4E (0.40) | KMT2AALDH1A1 | |
| SCHEMBL13988533 | 0.69 | KMT2A (0.50) | KMT2AALDH1A1MAPK1MAOBMAPT | |
| SCHEMBL14015237 | 0.68 | ALDH1A1 (0.58) | KMT2AALDH1A1MAPK1MAOBMAPT | |
| SCHEMBL13988494 | 0.68 | KMT2A (0.51) | KMT2AALDH1A1MAPK1MAOBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080311099-A1 | Pyridoxal-5-Phosphate and Related Compounds in Combination With Therapeutic Cardiovascular Compounds for Treating Angina | MEDICURE INTERNATIONAL INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080311099-A1 | Pyridoxal-5-Phosphate and Related Compounds in Combination With Therapeutic Cardiovascular Compounds for Treating Angina | MEDICURE INTERNATIONAL INC. | 2008-12-18 | — | — | US | disclosed |
| US-7442689-B2 | Cardioprotective phosphonates and malonates | MEDICURE INTERNATIONAL INC. (BB) | 2008-10-28 | — | — | US | disclosed |
| US-7442689-B2 | Cardioprotective phosphonates and malonates | MEDICURE INTERNATIONAL INC. (BB) | 2008-10-28 | — | — | US | disclosed |
| US-20070167411-A1 | Compositions for treating angina | MEDICURE INTERNATIONAL INC. (BB) | 2007-07-19 | — | — | US | disclosed |
| US-20070167411-A1 | Compositions for treating angina | MEDICURE INTERNATIONAL INC. (BB) | 2007-07-19 | — | — | US | disclosed |
| US-20070032456-A1 | Modulation of cell death | MEDICURE INC. (CA) | 2007-02-08 | — | — | US | disclosed |
| US-20070032456-A1 | Modulation of cell death | MEDICURE INC. (CA) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167411-A1 | Compositions for treating angina | PNPO, PYGM, PLPBP | KMT2A 3440/4885ALDH1A1 1367/4885MAPK1 4279/4885 |
| US-20080311099-A1 | Pyridoxal-5-Phosphate and Related Compounds in Combination With Therapeutic Cardiovascular Compounds for Treating Angina | ALOX5, PNPO, KCNMB1 | KMT2A 2206/4885ALDH1A1 1179/4885MAPK1 2426/4885 |
| US-20070032456-A1 | Modulation of cell death | CASP6, CASP3, CASP5 | KMT2A 4133/4885ALDH1A1 3492/4885MAPK1 2411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.